

Jean-Nol Talbot

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11400828/jean-noel-talbot-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

1,668
citations

20
h-index

40
g-index

66
ext. papers

2,023
ext. citations

4.2
avg, IF

4.06
L-index

#	Paper	IF	Citations
55	The EANM practice guidelines for parathyroid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2801-2822	8.8	22
54	Patient external dose rate after Lu-DOTATATE therapy: factors affecting its decrease and predictive value. <i>International Journal of Medical Sciences</i> , 2021 , 18, 2725-2735	3.7	
53	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal F-fluorocholine PET/CT: 1084 examinations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2823-2830	8.8	5
52	A comparative study of peptide-based imaging agents [Ga]Ga-PSMA-11, [Ga]Ga-AMBA, [Ga]Ga-NODAGA-RGD and [Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models. <i>Nuclear Medicine and Biology</i> , 2020 , 84-85, 88-95	2.1	6
51	Comparison of F-sodium fluoride PET/CT, F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. <i>BMC Medical Imaging</i> , 2020 , 20, 25	2.9	3
50	Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact. <i>Scientific Reports</i> , 2020 , 10, 21044-9	4.9	14
49	Rare Extramedullary Cardiac Involvement of Recurrent Multiple Myeloma Suspected on 18F-FDG and Confirmed on 18F-Fluorocholine. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 916-918	1.7	
48	Incidental Metastatic Melanoma Identified on 18F-FDOPA PET/CT With Confirmation by Histology. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 817-818	1.7	2
47	F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism. <i>World Journal of Surgery</i> , 2020 , 44, 3761-3769	3.3	8
46	Ga-DOTATOC PET/CT in detecting neuroendocrine tumours responsible for initial or recurrent paraneoplastic Cushing's syndrome. <i>Endocrine</i> , 2020 , 67, 708-717	4	7
45	Preclinical Evaluation of Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2776-2784	5.6	13
44	[Ga]RGD Versus [F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide. <i>Molecular Imaging and Biology</i> , 2019 , 21, 297-305	3.8	7
43	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. <i>Gastroenterology</i> , 2019 , 157, 807-822	13.3	8
42	18F-Fluorocholine PET/CT Imaging of Brown Tumors in a Patient With Severe Primary Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 971-974	1.7	5
41	Impact of sodium F-fluoride PET/CT, F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. <i>World Journal of Urology</i> , 2019 , 37, 1587-1595	4	5
40	Vertebral metastases from neuroendocrine tumours: How to avoid false positives on Ga-DOTA-TOC PET using CT pattern analysis?. <i>European Radiology</i> , 2018 , 28, 3943-3952	8	8
39	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. <i>PLoS ONE</i> , 2018 , 13, e0191487	3.7	14

38	Comparison and evaluation of two RGD peptides labelled with Ga or F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. <i>Oncotarget</i> , 2018 , 9, 19307-19316	3.3	10
37	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , 2018 , 19, e534-e545	21.7	65
36	Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1230-1235	8.9	8
35	Reply. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 172	8.8	
34	Tumor Heterogeneity Detected by 68Ga DOTATOC and 18F-FDG PET/CTs in One Malignant Insulinoma With Involvement of the Portal Splenic Confluence and Ovarian Metastases. <i>Clinical Nuclear Medicine</i> , 2016 , 41, 874-876	1.7	6
33	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1995-2004	8.8	50
32	68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. <i>Anticancer Research</i> , 2016 , 36, 4459-66	2.3	9
31	A Method to Improve the Semiquantification of 18F-FDG Uptake: Reliability of the Estimated Lean Body Mass Using the Conventional, Low-Dose CT from PET/CT. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 753-8	8.9	12
30	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. <i>Medicine (United States)</i> , 2015 , 94, e1701	1.8	113
29	Use of choline PET for studying hepatocellular carcinoma. <i>Clinical and Translational Imaging</i> , 2014 , 2, 103-113	2	12
28	Strengths and limitations of using fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. <i>Expert Review of Endocrinology and Metabolism</i> , 2014 , 9, 477-485	4.1	1
27	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. <i>Radiology and Oncology</i> , 2014 , 48, 20-8	3.8	7
26	Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4531-6	5.6	101
25	Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. <i>Clinical Nuclear Medicine</i> , 2014 , 39, 951-9	1.7	8
24	Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. <i>Radiology and Oncology</i> , 2014 , 48, 228-34	3.8	38
23	18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 943-66	8.8	89
22	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. <i>Nuclear Medicine Communications</i> , 2012 , 33, 757-65	1.6	20
21	Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. <i>Nuclear Medicine Communications</i> , 2012 , 33, 775-9	1.6	27

20	Novel DOTA-neurotensin analogues for ¹¹¹ In scintigraphy and ⁶⁸ Ga PET imaging of neurotensin receptor-positive tumors. <i>Bioconjugate Chemistry</i> , 2011 , 22, 1374-85	6.3	42
19	Detection of bronchioloalveolar cancer by means of PET/CT and ¹⁸ F-fluorocholine, and comparison with ¹⁸ F-fluorodeoxyglucose. <i>Nuclear Medicine Communications</i> , 2010 , 31, 389-97	1.6	41
18	Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of ¹⁸ F-fluorocholine and ¹⁸ F-FDG in patients with cirrhosis or chronic liver disease. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1699-706	8.9	153
17	Application diagnostique de la tomographie par émission de positons en France. De la gamma-caméra modifiée à la machine hybride TEP/TDM.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2010 , 194, 1559-1579	0.1	
16	Impact of fluorodihydroxyphenylalanine- ¹⁸ F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1295-301	5.6	58
15	Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 396-405	8.8	20
14	Current evaluation of the clinical utility of Fluoromethylcholine-(¹⁸ F) PET/CT in Prostate Cancer. <i>Brazilian Archives of Biology and Technology</i> , 2008 , 51, 71-75	1.8	1
13	FDOPA-(¹⁸ F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. <i>Brazilian Archives of Biology and Technology</i> , 2007 , 50, 77-90	1.8	9
12	Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat study. <i>Nuclear Medicine Communications</i> , 2007 , 28, 813-22	1.6	9
11	PET/CT in patients with hepatocellular carcinoma using [¹⁸ F]fluorocholine: preliminary comparison with [¹⁸ F]FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 1285-9	8.8	112
10	¹⁸ F-choline PET/CT for initial staging of advanced prostate cancer. <i>American Journal of Roentgenology</i> , 2006 , 187, W618-21	5.4	16
9	Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 1455-62	8.9	78
8	Impact of CT and ¹⁸ F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 340-5	4	107
7	Impact of computed tomography and ¹⁸ F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 1432-41	4	98
6	Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine ¹²³ technetium Tc ^{99m} sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. <i>American Journal of Kidney Diseases</i> , 2005 , 45, 344-52	7.4	46
5	Detection of recurrent colorectal carcinoma by ¹⁸ F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. <i>Nuclear Medicine Communications</i> , 2004 , 25, 105-13	1.6	4
4	Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. <i>Clinical Nuclear Medicine</i> , 2003 , 28, 771-2	1.7	24
3	Fluorodeoxyglucose imaging using a coincidence gamma camera to detect head and neck squamous cell carcinoma and response to chemotherapy. <i>Annals of Otolaryngology and Rhinology and Laryngology</i> , 2002 , 111, 763-71	2.1	7

2	CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 1249-57	4	104
1	Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin. <i>Annals of Otolaryngology and Laryngology</i> , 2000 , 109, 755-60	2.1	4